MyPerioPath® Antibiotic Option

MyPerioPath® results provide guidance to the health care provider regarding the bacterial cause to a patient’s periodontal disease and/or risk of complicating other systemic diseases such as cardiovascular disease¹, diabetes², certain cancers³, brain health⁴, musculoskeletal health⁵, and pregnancy outcomes⁶. The health care provider will consider several modes of therapy to help address the pathogenic bacteria and the following therapy will conduct a post-therapy test to objectively measure the impact of the applied therapy on the bacterial profile.

The MyPerioPath® treatment consideration section of the report provides an overview of possible therapies to be determined by the health care provider. This section is thorough; however, it does not include all therapy options. A health care provided should never feel limited by these considerations as they are just that – “considerations.”

Some health care providers opt to utilize the systemic antibiotic option in addition to mechanical debridement. The systemic antibiotic option printed on the report refers to a resource labeled the MyPerioPath® Antibiotic Options. In most cases, when the pathogenic bacteria exceed the Therapeutic Threshold (bold black lines), an algorithm is applied for selecting the evidence-based recommendation(s). If the bacteria levels do not reach the threshold or the option was omitted intentionally and the provider assesses the patient would benefit from antibiotic therapy, then the health care provider can refer to the MyPerioPath® Antibiotic Options for a possible antibiotic selection consideration.

The below video highlights the MyPerioPath® Antibiotic Option.

References:

1. Meurman JH, Sanz M, Janket SJ. Oral health, atherosclerosis, and cardiovascular disease. Crit Rev Oral Biol Med 2004;15:403-13.
2. Kumar M, Mishra L, Mohanty R, Nayak R. “Diabetes and gum disease: the diabolic duo”. Diabetes Metab Syndr 2014;8:255-8.
3. Jacob JA. Study Links Periodontal Disease Bacteria to Pancreatic Cancer Risk. JAMA 2016;315:2653-4.
4. Dominy SS, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5:eaau3333.
5. Johansson L, Sherina N, Kharlamova N, et al. Concentration of antibodies against Porphyromonas gingivalis is increased before the onset of symptoms of rheumatoid arthritis. Arthritis Res Ther 2016;18:201.
6. Persson GR, Hitti J, Paul K, et al. Tannerella forsythia and Pseudomonas aeruginosa in subgingival bacterial samples from parous women. J Periodontol 2008;79:508-16.
7. For more information on how to become an OralDNA Provider – scan HERE: 

• Author
• Recent Posts

Diane Larson RDH, BSDH

Diane Larson, RDH, BSDH brings over two decades of distinguished dental expertise to her role. As an esteemed member of the ADHA and MnDHA, Diane has gracefully transitioned from hands-on patient care to a role focused on empowering clinicians to deliver exceptional care through evidence-based treatment plans. She considers herself an integral extension of every team that leverages OralDNA services, passionately working to enhance the quality of healthcare delivery.
Diane’s holistic approach is enriched by her extensive knowledge of nutrition, seamlessly integrating it into her practice. Proudly rooted in the Midwest, she makes her home in Minnesota with her husband, where she continues to contribute meaningfully to the dental community, driven by a deep commitment to excellence and patient care.

Latest posts by Diane Larson RDH, BSDH (see all)

• Olympic Spirit: Achieving Gold in Healthcare - August 16, 2024
• The Winning Team: The Healthcare Provider & The Clinical Laboratory - April 12, 2024
• An Introduction to the History of Clinical Laboratory Testing - October 13, 2023